Dedicated to solving pandemic-sized problems
Pardes is applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates. The company is developing lead product PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated disease (i.e. COVID-19). Frazier Senior Advisor Mike Varney serves on the company’s board of directors and scientific advisory board.